Mednet Logo
Community

Are there clinical features that would lead you to consider combining SBRT + immunotherapy in a high risk early stage NSCLC?

Community PollStarted

What clinical features that would lead you to consider enrolling early stage NSCLC patients to an SBRT/immunotherapy trial?

94 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of California at Davis
Answered on

I currently only use SBRT + immunotherapy in medically inoperable, early-stage NSCLC on clinical trial, as it is not yet a standard of care for early-stage disease. There are several randomized phase 3 trials currently testing immunotherapy in this patient population, however. On SWOG/NRG S1914, a p...

Join for free or sign in to see the full answer